Belldegrun Arie's Form 4 filing
Allogene Therapeutics, Inc. (ALLO) · filed May 20, 2024
- Accession no.
- 0001737287-24-000042
- Filed
- May 20, 2024
- Trade date
- May 16, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $5.00M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Belldegrun ArieCIK 0001296549 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 16, 2024 | Common Stock | AGrant or awardAcquired | +344,828 | $2.90 | +$1,000,001.2 | 539,867 | Indirect | |
| May 16, 2024 | Common Stock | PPurchaseAcquired | +1,724,137 | $2.90 | +$4,999,997.3 | 1,724,137 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.